Steve is the Editor in Chief, coordinating the daily news articles and social media content of the organization. He is an active journalist in the aging research and biotechnology field and has to date written over 600 articles on the topic, interviewed over 100 of the leading researchers in the field, hosted livestream events focused on aging, as well as attending various medical industry conferences.
He served as a member of the Lifespan.io board since 2017 until the org merged with SENS Research Foundation and formed the LRI.
His work has been featured in H+ magazine, Psychology Today, Singularity Weblog, Standpoint Magazine, Swiss Monthly, Keep me Prime, and New Economy Magazine.
Steve is one of three recipients of the 2020 H+ Innovator Award and shares this honour with Mirko Ranieri – Google AR and Dinorah Delfin – Immortalists Magazine. The H+ Innovator Award looks into our community and acknowledges ideas and projects that encourage social change, achieve scientific accomplishments, technological advances, philosophical and intellectual visions, author unique narratives, build fascinating artistic ventures, and develop products that bridge gaps and help us to achieve transhumanist goals.
Steve has a background in project management and administration which has helped him to build a united team for effective fundraising and content creation, while his additional knowledge of biology and statistical data analysis allows him to carefully assess and coordinate the scientific groups involved in the project.
Related Organizations
Articles from this author
May 18, 2026
We have spoken with Reason from Repair Biotechnologies about his company's lead candidate, REP-0004, a drug targeting the liver to reduce excess intracellular free cholesterol. The FDA has granted Repair Bio an orphan drug indication, and the company is aiming for clinical trials by mid-2027. Our conversation also touches on the regulatory challenges and the...
May 14, 2026
Most cardiovascular trials focus on lowering LDL cholesterol or reducing inflammation to slow disease progression. UDP-003 targets the root cause: toxic 7-ketocholesterol (7KC) inside macrophages and soft plaques. It is designed to convert bloated foam cells back into healthy macrophages that can actively clear the hard plaque. This clinical trial took place at CMAX, a...
April 23, 2026
For those of us in the Northern Hemisphere, spring is here. This is a time of renewal and hope for better times ahead, echoing what our field is trying to achieve: the rejuvenation of aging cells and tissues to keep older people free from age-related diseases. On that note, let’s take a look at what...
April 08, 2026
The FDA views aging as an inevitability, not a medical target. However, with Life Biosciences moving the first cellular reprogramming therapy into human trials this year, things might be changing there. If this technique works in resetting the biological age of the human eye, the entire multibillion-dollar longevity industry could move to the center of...
December 11, 2025
Happy holidays! Winter is in full swing for those of us in the Northern Hemisphere. It is a time for cozy nights by the fire and a great time to catch up on what has been happening at Lifespan News and LRI. A cultural intelligence platform for effective advocacy We are delighted to announce that...
November 12, 2025
The idea of living longer, healthier lives thanks to rejuvenation biotechnology has steadily become more common. Gradually increasing numbers of articles are discussing this idea, especially as science is starting to catch up and may eventually even deliver on it. With that in mind, I was pleasantly surprised this week to be greeted by an...





